Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Legend Biotech (LEGN) Operating Expenses: 2019-2025

Historic Operating Expenses for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to -$147.9 million.

  • Legend Biotech's Operating Expenses fell 13.03% to -$147.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$412.3 million, marking a year-over-year decrease of 0.11%. This contributed to the annual value of $413.4 million for FY2024, which is 8.19% up from last year.
  • As of Q3 2025, Legend Biotech's Operating Expenses stood at -$147.9 million, which was down 12.97% from -$130.9 million recorded in Q2 2025.
  • Legend Biotech's 5-year Operating Expenses high stood at -$79,836 for Q1 2021, and its period low was -$148.0 million during Q2 2024.
  • Moreover, its 3-year median value for Operating Expenses was -$130.8 million (2024), whereas its average is -$107.2 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first tumbled by 117,898.15% in 2022, then soared by 99.87% in 2023.
  • Quarterly analysis of 5 years shows Legend Biotech's Operating Expenses stood at -$103.6 million in 2021, then declined by 3.66% to -$107.4 million in 2022, then surged by 99.87% to -$134,390 in 2023, then dropped by 3.16% to -$138,633 in 2024, then dropped by 13.03% to -$147.9 million in 2025.
  • Its Operating Expenses was -$147.9 million in Q3 2025, compared to -$130.9 million in Q2 2025 and -$133.4 million in Q1 2025.